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FoxO1 is a member of the FoxO
(Forkhead box-containing, O subfamily)
family of transcription factors. The FoxO
proteins FoxO1, FoxO3a, FoxO4, and
FoxO6 are evolutionarily conserved tran-
scription factors involved in a variety of
cellular processes (Tran et al., 2003). In
mammals, FoxO proteins have been
shown to play a role in processes such
as cell cycle control, differentiation,
stress response, and apoptosis. The
investigation of the signaling pathways
that regulate the transcriptional activity
of FoxO proteins, as well as the identifi-
cation of FoxO target genes, has yielded
evidence that FoxO proteins possess
tumor suppressive functions.
The proapoptotic activity of FoxO pro-
teins is mediated through the transcrip-
tional regulation of several genes such as
TRAIL, FasL, and Bim. The role of FoxO
factors in inducing cell cycle arrest is
achieved by transcriptional repression of
positive cell cycle regulators such as
cyclins D1 and D2, as well as transcrip-
tional induction of negative cell cycle reg-
ulators such as p27 and p130 (Tran et al.,
2003). FoxO proteins also induce stabi-
lization of p27 protein by an as-yet-
unknown mechanism (Nakamura et al.,
2000). Significantly, FoxO-mediated cell
cycle arrest is at least partially dependent
on p27, as p27-deficient fibroblasts lose
their ability to stop proliferating in
response to FoxO protein expression
(Medema et al., 2000).
FoxO family members are negatively
regulated by the phosphoinositide 3-
kinase (PI3K)-Akt pathway, which is
induced by mitogenic and survival sig-
nals and is overactivated in a variety of
tumors (Tran et al., 2003). Activation of
the Akt kinase results in the phosphory-
lation of FoxO proteins on conserved
residues, leading to their nuclear exclu-
sion, inhibition, and degradation. In addi-
tion, FoxO3a is also phosphorylated by a
different kinase, IKKβ, that, similarly to
Akt, triggers the degradation of the tran-
scription factor (Hu et al., 2004).
Several studies have demonstrated
that the cellular abundance of FoxO1
and FoxO3a is regulated by the ubiquitin-
proteasome system (Aoki et al., 2004;
Hu et al., 2004). The degradation of
FoxO1 was shown to be dependent on
phosphorylation by Akt; however, the
ubiquitination machinery targeting its
degradation has remained elusive until
recently. Both the dependency on phos-
phorylation and the role of FoxO1 and
FoxO3a in cell cycle progression sug-
gest that both factors may be substrates
of one of many SCF (Skp1, Cul1, F box
protein) ubiquitin ligase complexes
(Cardozo and Pagano, 2004).
A recent paper published in PNAS
(Huang et al., 2005) now demonstrates
that SCFSkp2 binds to FoxO1 and induces
its ubiquitylation following Akt phosphor-
ylation at Ser-256. The authors initially
noticed that FoxO1 and Skp2 protein
expression patterns inversely correlate
during the cell cycle, an observation that
provided a hint that FoxO1 may be a sub-
strate of the F box protein Skp2. Using
reporter gene assays, the authors show
that Skp2-mediated degradation of
FoxO1 inhibits its transcriptional activity.
Furthermore, enforced expression of
Skp2 eliminates the apoptotic effect of
FoxO1 on prostate carcinoma cells, sug-
gesting that Skp2 is able to inhibit the
tumor suppressor activity of FoxO1.
Conversely, Skp2 has no effect on the
apoptotic response induced by a degra-
dation-resistant mutant of FoxO1. In
addition, the authors found that the lev-
els of FoxO1 and Skp2 inversely corre-
late in a mouse lymphoma model.
Downregulation of Skp2 by RNA interfer-
ence resulted in the accumulation of
FoxO1 protein in malignant T cells, sug-
gesting that Skp2 upregulation is central
to controlling FoxO1 protein levels in this
type of tumor. Interestingly, the degrada-
tion of the related protein FoxO3a is
dependent on the phosphorylation of a
domain similar to that recognized by the
F box protein βTrcp in its substrates (Hu
et al., 2004). It is thus possible that the
degradation of FoxO3a is also mediated
by an SCF ubiquitin ligase.
Skp2 plays an important role in the
timely degradation of several proteins
involved in the negative control of the cell
division cycle, such as p27, p21 and
p130. In addition, Skp2-mediated ubiqui-
tylation appears to stimulate the tran-
scriptional activity of c-Myc and possibly
b-Myb and E2F1. The new finding by
Huang et al. reveals an additional mecha-
nism by which Skp2 controls the levels of
p27. In addition to directly regulating p27
protein stability by ubiquitylation, Skp2 is
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Skp2, the FoxO1 hunter
Skp2 is an oncoprotein that mediates the degradation of several negative regulators of the cell cycle to promote cell prolif-
eration. A recent report by Huang and colleagues reveals that Skp2 directs the ubiquitylation and subsequent degradation
of FoxO1, a member of the FoxO family of transcription factors. Since FoxO proteins possess tumor suppressor functions,
this new finding suggests a new mechanism by which Skp2 may favor tumorigenesis.
Figure 1. Skp2 directs the ubiquitylation and
subsequent degradation of the cell cycle
inhibitors p27 and p21 following their
phosphorylation by CDKs
Huang et al. now demonstrate that Skp2 also
promotes the degradation of FoxO1 follow-
ing its phosphorylation by Akt. FoxO1 induces
the expression of p27, and in response to
TGFβ signaling, it forms transcriptional com-
plexes with SMAD3 and SMAD4 to induce the
expression of p21. Therefore, Skp2 controls
the protein levels of p21 and p27 via two
routes: directly by controlling p27 and p21
protein levels, and indirectly by controlling
the protein levels of FoxO1. To add a further
layer of complexity, the PI3K-Akt pathway
appears to control all these players: it down-
regulates FoxO1, upregulates Skp2, and
inactivates p21 and p27 by inducing their
nuclear exclusion. Finally, it is possible that
FoxO1 may negatively regulate Skp2 expres-
sion, since Skp2 is upregulated in cells
expressing the dominant negative Pax3-
FoxO1 chimeric protein.
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now suggested to indirectly control p27
levels by promoting the degradation of
FoxO1, thus inhibiting p27 transcription.
Interestingly, FoxO proteins were recently
demonstrated to cooperate with the
SMAD tumor suppressor proteins in
inducing the expression of p21, a protein
closely related to p27 (Seoane et al.,
2004). In response to TGFβ signaling,
FoxO factors form transcriptional com-
plexes with SMAD3 and SMAD4 that bind
and activate the p21 promoter. Since
Skp2 also promotes the degradation of
p21 during S phase, the protein levels of
both p27 and p21 are under the dual con-
trol of Skp2 and FoxO proteins (see
Figure 1). Interestingly, as a further evi-
dence of the connection among these dif-
ferent players, Skp2 mRNA expression is
induced in response to PI3K signaling
(Mamillapalli et al., 2001), and Akt can
directly phosphorylate p21 and p27,
resulting in their nuclear exclusion and
thus eliminating their ability to inhibit the
activity of CDKs (Bloom and Pagano,
2003).
Deregulation of FoxO factors seems
to play a role in oncogenesis (Tran et al.,
2003). In fact, FoxO genes were initially
identified at sites of chromosomal
translocations in several tumors such as
leukemias and alveolar rhabdomyosar-
comas (ARMS). In the latter, the translo-
cation results in a fusion between the
DNA binding domain of the transcription
factors PAX3 or PAX7 to the transactiva-
tion domain of FoxO1. In light of FoxO’s
tumor suppressor function, it was sug-
gested that the chimeric protein may act
in a dominant negative manner and inac-
tivate FoxO1 function. Accordingly,
although haploinsufficiency of FoxO1
does not significantly increase cancer
incidence, Pax3-FoxO1 homozygous
mice develop ARMS in an Ink4a/Arf- or
p53-deficient background (Keller et al.,
2004). Interestingly, it was shown that in
Pax3-FoxO1-expressing cells, Skp2 is
upregulated, resulting in a decrease of
p27 protein but not mRNA levels (Zhang
and Wang, 2003). This shows that the
fusion protein regulates Skp2 expression
by a still-to-be-determined mechanism.
Another way to deregulate FoxO1 is
via the inactivation of the tumor suppres-
sor PTEN, an inhibitor of Akt that is com-
monly mutated in a variety of tumors. In
cancer cell lines deficient in PTEN,
FoxO1 is localized in the cytoplasm and
displays decreased transcriptional activi-
ty (Nakamura et al., 2000). Although it
has not been investigated, one would
expect a destabilization of FoxO1 in
PTEN-deficient cells due to Akt activation
and upregulation of Skp2 (Mamillapalli et
al., 2001).
The involvement of the Skp2-p27
axis in tumorigenesis is also well docu-
mented (Bloom and Pagano, 2003). Of
all known Skp2 substrates, p27 is
thought to be central to its oncogenic
effect. This notion is supported by both
animal models and examination of
human tumors. For example, most of the
cellular and cell cycle abnormalities pre-
sent in Skp2-deficient mice are abol-
ished in Skp2;p27 double knockout mice.
Moreover, Skp2 expression inversely
correlates with p27 levels in a variety of
human tumors, including lymphomas,
breast carcinomas, colorectal carcino-
mas, and lung cancers. Importantly,
downregulation of p27 protein levels
observed in human tumors does not cor-
relate with a decrease in p27 mRNA lev-
els. Instead, enhanced proteolysis
represents a major mechanism to elimi-
nate this tumor suppressor protein.
The finding by Huang et al. adds to
accumulating evidence that strongly sug-
gests an involvement of FoxO proteins in
tumorigenesis. It will be of great interest
to evaluate the expression of FoxO1 pro-
tein in human tumors and its correlations
to the levels of Skp2 and p27, as well as
to Akt activity and clinical outcome. A
prediction is that in aggressive tumors
overexpressing Skp2 and displaying
increased Akt activity, levels of FoxO1
are low. It is possible that in these
tumors, p27 expression is decreased not
only at the protein level but also at the
transcript level. Finally, it will be interest-
ing to evaluate whether, in addition to the
translocations described in ARMS, muta-
tions in the FoxO1 gene are present in
certain human tumors, and whether they
correlate with high Skp2 levels. These
studies will further enhance our under-
standing of the role of FoxO1 in tumori-
genesis.
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